An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.
A legfontosabb adatok
- Ki végzi
- Lupin Ltd.
- Hol
- Belgium, Dánia, Egyesült Királyság, Németország, Olaszország és Spanyolország6 helyszín, 6 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Csak meghívásos
- Fázis
- 3. fázis
- Résztvevők
- 176 fő, tervezett
- Kezdés
- 2025. szept. 12.
- Várható befejezés
- 2028. júl. 6.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Mexiletine granules for prolonged-release oral suspension
- A regiszteradat frissítve
- 2026. január 26.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for people with myotonic dystrophy type 1 or type 2 who have completed the MEX-DM-302 study. They will take mexiletine PR once a day.
- Életkor
- 16 years and older
- Nem
- Male and female. Women cannot be pregnant.
- A betegség stádiuma
- Myotonic dystrophy type 1 (DM1) or type 2 (DM2), confirmed by a genetic test. People with DM1 need a muscle impairment (MIRS) score of 2, 3 or 4. People need enough finger strength to grip a hand-strength device.
- Korábbi kezelés
- People must have completed the MEX-DM-302 study. No anti-myotonic treatment within 4 weeks before the start, or 5 half-lives if that is longer.
- Biomarker vagy leletérték
- Genetic test confirming DM1 or DM2. BMI of 18.5 kg/m2 to 30 kg/m2, and weight of at least 45 kg (99 lb). Blood potassium from 3.5 to 5.0 mmol/L and magnesium of at least 1.7 mg/dL.
A részvétel fő kizáró okai
- Pregnant or breastfeeding
- Serious heart problems, heart rhythm problems, a pacemaker or an implanted defibrillator
- Severe kidney problems (GFR < 30 mL/min) or liver tests > 3 times the upper limit of normal
- Using a wheelchair or confined to bed, or more than 5 falls in the past 12 months
- Allergy to mexiletine or local anesthetics
A regiszter feltételei, szó szerint
Mind a 24 feltétel megnézéseKevesebb
Ki vehet részt
- DM1 or DM2 diagnosis confirmed genetically
- Ability to comprehend and willingness to sign an informed consent (ICF) or ICF of the parent(s)/legal guardian and written assent from the patient (if patient < 18 years of age)
- Ability to understand the study requirements including intention to stay in the study until the end-of-study visit at 26 weeks of treatment
- Male or non-pregnant female ≥16 years of age
- Body Mass Index (BMI) of 18.5 kg/m2 to 30 kg/m2, and weight ≥45 kg
- Female patients of childbearing potential must be using a highly effective form of birth control for the duration of the study and for at least 7 days after last dose of study drug
- No significant cardiac abnormalities as determined by a cardiologist's assessment
- Have sufficient finger flexor strength to grasp the handle of the dynamometer used to measure myotonia
- DM1 patients only - Muscular impairment rating scale (MIRS) score of 2, 3 or 4
Ki nem vehet részt
- Have any one of the following medical conditions: uncontrolled diabetes mellitus, cancer other than skin cancer less than five years previously (e.g., basal-cell carcinoma (BCC) and squamous-cell carcinoma (SCC) of skin allowed), multiple sclerosis, seizure disorders, or other serious medical illness
- Intake of any anti-myotonic treatment within 4 weeks prior to baseline (Day 1) or 5 half-lives, whichever is longer such as metformin, such as propafenone, flecainide, lamotrigine, carbamazepine or any other channel-blocker/ anticonvulsive drugs
- Use of any concomitant medications that could increase the cardiac risk
- Participation in another interventional clinical study during the last 3 months or 5 half-lives of the investigational medicinal product, whichever is longer (with the exception of participation in the previous MEX-DM-302 study)
- Medical conditions which could interfere with muscle function such as infections, trauma, fractures, or planned surgery
- Medical conditions that could affect hand functioning including but not limited to rheumatoid arthritis, Dupuytren's contracture, hand deformity, etc
- Severe arthritis or medical condition (other thanDM1/DM2) that would significantly impact ambulation
- Known allergy to mexiletine or any local anesthetics
- Severe renal impairment (glomerular filtration rate (GFR) < 30 mL/min)
- Preexisting elevated liver function tests > 3 times the upper limit of normal (ULN) on Day 1 (alanine transaminase (ALT)/aspartate transaminase (AST), gamma-glutamyl transferase (GGT)) and/or any abnormal chemistry, hematology or urine lab considered clinically significant by investigator
- Serum potassium values < 3.5 mmol/L or > 5.0 mmol/L or serum magnesium values < 1.7 mg/dL. Electrolytic imbalance such as hypokalaemia, hyperkalaemia or hypomagnesaemia may increase the proarrhythmic effects of mexiletine. Electrolyte imbalances need to be corrected before administering mexiletine and will be monitored throughout treatment
- Any cardiac safety associated condition including any of the following criteria detected by cardiac evaluations including 24-hr Holter monitor, echocardiogram and clinical evaluations:; PR interval ≥240 ms or QRS duration ≥120 ms on resting ECG; Personal history of 3rd degree or 2nd degree type 2 atrioventricular block or sinus node dysfunction with pauses ≥3 seconds, complete bundle branch block, bifascicular and trifascicular block or any heart block susceptible to evolve to complete heart block; Personal history of sustained atrial fibrillation, flutter or tachycardia (duration >30 seconds); Personal history of non-sustained (ventricular triplets or more) or sustained ventricular tachycardia; Myocardial infarction (acute or past) or coronary artery stenosis >50%, presence of abnormal Q waves; New York Heart Association (NYHA) Class II to IV heart failure; Left ventricular systolic dysfunction with ejection fraction <50%; Sinus node dysfunction (including ECG sinus rate <50 beats per minute (BPM)); Co-administration of antiarrhythmics inducing torsades de pointes (class Ia: quinidine, procainamide, disopyramide, ajmaline; class Ic: encainide, flecainide, propafenone, moricizine; class III: amiodarone, sotalol, ibutilide, dofetilide, dronedarone, vernakalant); Co-administration of other classes of antiarrhythmics (class Ib: lidocaine, phenytoin, tocainide; class II: propranolol, esmolol, timolol, metoprolol, atenolol, carvedilol, bisoprolol, nebivolol; class IV: verapamil, diltiazem); Patients with implantable cardioverter defibrillators (ICDs) and pacemakers are excluded; Presence of symptomatic coronary artery disease
- Are pregnant or lactating
- High incidence of falls or fall-associated fractures (>5 falls during the past 12 months)
- Wheelchair-bound or bed-ridden
Hol van ez a vizsgálat?
6 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is an open-label extension study intended to evaluate the long-term safety and efficacy of mexiletine PR in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2) who have completed the parent study MEX-DM-302.
A vizsgálat csoportja
- Mexiletine prolonged-release (PR)Egyéb csoport
Mexiletine PR 167 mg (mexiletine HCl 200 mg) Mexiletine PR 333 mg (mexiletine HCl 400 mg) OR Mexiletine PR 500 mg (mexiletine HCl 600 mg)
Kezelés: Mexiletine granules for prolonged-release oral suspension
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed the MEX-DM-302 Study (ATLAS Study)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2026. január 26.